9. Literatur

Barnsdale L, Graham L und Gounari X (2017) *National Naloxone Programme Scotland. Monitoring Report 2016/17.*

Bremer V, Cai W, Gassowski M, et al. (2016) *Robert Koch-Institut. Abschlussbericht der Studie 'Drogen und chronische Infektionskrankheiten in Deutschland' (DRUCK-Studie)*. Berlin.

Bundeskriminalamt (2023) *Rauschgiftkriminalität. Bundeslagebild 2022*. Wiesbaden: Bundeskriminalamt.

Campbell ND (2020) *OD: Naloxone and the Politics of Overdose*. Inside technology. Cambridge, MA: The MIT Press.

CDC (2024) Lifesaving Naloxone. Available at: https://www.cdc.gov/stop-overdose/caring/naloxone.html (accessed 5 August 2024).

Coffin PO und Sullivan SD (2013) Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Annals of Internal Medicine* 158(1). American College of Physicians: 1–9.

Colledge-Frisby S, Rathnayake K, Nielsen S, et al. (2023) Injection drug use frequency before and after take-home naloxone training. *JAMA Network Open* 6(8): e2327319.

Cornish R, Macleod J, Strang J, et al. (2010) Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ (Clinical research ed.)* 341. BMJ.

Dettmer K (2018) Berlin - die Vorreiter_innen. Der Beginn der Naloxonverschreibung für Drogenkonsument_innen in Deutschland: ein Erfahrungsbericht. In: Dichtl A, Stöver H, und Dettmer K (eds) *Leben retten mit Naloxon: Erfahrungen aus Deutschland, Europa und den USA*. Frankfurt am Main: Fachhochschulverlag, pp. 46–61.

Dettmer K, Saunders B und Strang J (2001) Take-home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. *BMJ : British Medical Journal* 322(7291): 895–896.

EMCDDA (2021) *Opioid-Related Deaths: Health and Social Responses*. Available at: https://www.emcdda.europa.eu/publications/mini-guides/opioid-related-deaths-health-and-social-responses_en#section5.

Ericson ØB, Eide D, Lobmaier P, et al. (2022) Risks and overdose responses: Participant characteristics from the first seven years of a national take-home naloxone program. *Drug and Alcohol Dependence* 240: 109645.

Essay Inf Sci. (1983) The Garfield E. John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigation of naloxone. (6): 121–130.

EUDA (2024) *Drug-induced deaths – the current situation in Europe (European Drug Report 2024)*. Lisbon: European Union Drugs Agency. Available at: https://www.euda.europa.eu/publications/european-drug-report/2024/drug-induced-deaths_en (accessed 19 September 2024).

https://doi.org/10.5771/9783748943235-117 https://www.inlibra.com/de/page/agb - Open Access - (cc) BY

Federer P (2015) Stand der Naloxonvergabe in Italien. In: Dichtl A und Stöver H (eds) *Naloxon - Überlebenshilfe im Drogennotfall*. Fachhochschulverlag Bd. 27. Frankfurt, M: Fachhochsch.-Verl, pp. 96–103.

Fleißner S, Stöver H und Schäffer D (2023) Take-Home Naloxon: Ein Baustein der Drogennotfallprophylaxe auch in Deutschland. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*. Epub ahead of print 26 May 2023. DOI: 10.1007/s00103-023-03705-4.

Håkansson A, Blomé MA, Isendahl P, et al. (2024) Distribution of intranasal naloxone to potential opioid overdose bystanders in Sweden: effects on overdose mortality in a full region-wide study. *BMJ Open* 14(1). British Medical Journal Publishing Group: e074152.

Harm Reduction International (2023) Global state of harm reduction: 2023 update to key data. Available at: https://hri.global/publications/global-state-of-harm-reduction-2023-update-to-key-data/ (accessed 5 August 2024).

Hill AB (1965) The environment and disease: association or causation? *Proceedings of the Royal Society of Medicine* 58(5): 295–300.

Horsburgh K und McAuley A (2018) Scotland's national naloxone program: The prison experience. *Drug and Alcohol Review* 37(4): 454–456.

Jamin D, Vanderplasschen W, Sys O, et al. (2021) "My first 48 hours out": drug users' perspectives on challenges and strategies upon release from prison. *Harm Reduction Journal* 18(1): 32.

Katzman JG, Bhatt S und Comerci GD (2022) Take-home naloxone at opioid treatment programs: A lifesaver. *Journal of Addiction Medicine* 16(6): 619–621.

Kraus L, Seitz N-N, Schulte B, et al. (2019) Estimation of the number of people with opioid addiction in Germany. *Deutsches Ärzteblatt international*. Epub ahead of print 1 March 2019. DOI: 10.3238/arztebl.2019.0137.

Kuckartz U und Rädiker S (2022) *Qualitative Inhaltsanalyse: Methoden, Praxis, Computerunterstützung: Grundlagentexte Methoden*. 5. Auflage. Grundlagentexte Methoden. Weinheim Basel: Beltz Juventa.

Langham S, Wright A, Kenworthy J, et al. (2018) Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research* 21(4): 407–415.

McDonald R und Strang J (2016) Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. *Addiction* 111(7): 1177–1187.

McDonald R, Lorch U, Woodward J, et al. (2018) Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. *Addiction (Abingdon, England)* 113(3): 484–493.

McDonald R, Eide D, Skurtveit S, et al. (2024) Pills and the damage done: the opioid epidemic as man-made crisis. *Frontiers in Public Health* 11.

Merrall ELC, Kariminia A, Binswanger IA, et al. (2010) Meta-analysis of drug-related deaths soon after release from prison. *Addiction (Abingdon, England)* 105(9): 1545–1554.

https://doi.org/10.5771/9783748943235-117 https://www.inlibra.com/de/page/agb - Open Access - (cc) BY

Merrall ELC, Bird SM und Hutchinson SJ (2013) A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996-2006. *Addiction (Abingdon, England)* 108(2): 377–384.

Moustaqim-Barrette A, Elton-Marshall T, Leece P, et al. (2019) *Environmental scan naloxone access and distribution in Canada*. Vancouver: Canadian Research Initiative in Substance Misuse (CRISM). Available at: https://doi.library.ubc.ca/10.14288/1.0379400 (accessed 24 November 2021).

Neumeier E, Bergmann H, Karachaliou K, et al. (in prep.) *Bericht 2024 des nationalen REITOX-Knotenpunkts an die EMCDDA (Datenjahr 2023/2024). Deutschland, Workbook Gesundheitliche Begleiterscheinungen und Schadensminderung.* München: Deutsche Beobachtungsstelle für Drogen und Drogensucht DBDD.

Olsen A, McDonald D, Lenton S, et al. (2018) Assessing causality in drug policy analyses: How useful are the Bradford Hill criteria in analysing take-home naloxone programs? *Drug and Alcohol Review* 37(4): 499–501.

Parmar MKB, Strang J, Choo L, et al. (2017) Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths. *Addiction (Abingdon, England)* 112(3): 502–515.

Rummel C, Lehner B und Kepp J (2024) Daten, Zahlen und Fakten. In: Deutsche Hauptstelle für Suchtfragen e.V. (ed.) *DHS Jahrbuch Sucht 2024*. Lengerich: Pabst Science Publishers, pp. 9–38.

Schäffer D (2020) Opioidbedingte Todesfälle in Deutschland - warum bleibt Naloxon weitgehend ungenutzt. In: *7. Alternativer Drogen- Und Suchtbericht*. Groß-Umstadt: Pabst, pp. 85–89.

Schmitt G (2018) Interview mit Gilbert Schmitt: Modellprojekt Take-Home-Naloxon im Saarland/in Saarbrücken. Genügt Saarland? In: Dichtl A, Stöver H, und Dettmer K (eds) *Leben retten mit Naloxon: Erfahrungen aus Deutschland, Europa und den USA*. Frankfurt am Main: Fachhochschulverlag, pp. 86–90.

Schneider S und Beisel L (2020) Überdosierungen von Heroin. *Public Health Forum* 28(4): 288–291.

Schneider S, Richter C, Niethammer R, et al. (2021) Fatal and Non-Fatal Heroin-Related Overdoses: Circumstances and Patterns. *Substance Use & Misuse* 56(13): 1997–2006.

Statista (2024) Drogentote in Deutschland bis 2023. Available at: https://de.statista.com/statistik/daten/studie/403/umfrage/todesfaelle-durch-den-konsum-illegaler-drogen/ (accessed 2 August 2024).

Strang J (2022) Take-Home Naloxone and the Prevention of Deaths from Heroin Overdose: Pursuing Strong Science, Fuller Understanding, Greater Impact. *European Addiction Research* 28(3): 161–175.

Strang J und Farrell M (1992) Harm minimisation for drug misusers. *BMJ : British Medical Journal* 304(6835): 1127–1128.

Strang J, Darke S, Hall W, et al. (1996) Heroin overdose: the case for take-home naloxone. *BMJ* 312(7044): 1435–1436.

https://doi.org/10.5771/9783748943235-117 https://www.inlibra.com/de/page/agb - Open Access - (cc) BY

Strang J, McDonald R, Campbell G, et al. (2019) Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. *Drugs* 79(13): 1395–1418.

Tse WC, Djordjevic F, Borja V, et al. (2022) Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply. *International Journal of Drug Policy* 100: 103513.

UNODC (2024) *Opium Poppy Cultivation. Afghanistan Drug Insights Volume 1.* UNODC. Available at: https://www.unodc.org/documents/crop-monitoring/Afghanistan/Afghanistan_Drug_Insights_V1.pdf (accessed 27 November 2024).

White SR, Bird SM, Merrall ELC, et al. (2015) Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors. *PLOS ONE* 10(11). Public Library of Science: e0141073.

WHO (2014) *Community Management of Opioid Overdose*. Geneva: World Health Organization. Available at: https://apps.who.int/iris/handle/10665/200009 (accessed 16 January 2022).

Wodarz N, Wolstein J, Wodarz-von Essen H, et al. (2019) Naloxon – Medizinische Grundlagen und internationale Erfahrungen. *SUCHT* 65(5). Hogrefe AG: 335–342.

Wodarz-von Essen H, Wolstein J, Pogarell O, et al. (2022) Take-Home-Naloxon für geschulte Opioidabhängige - Erfahrungen zum Umgang mit Überdosierungsnotfällen. *NOTARZT* 38(03): 138–142.

Wodarz-von Essen H, Pogarell O, Wolstein J, et al. (2021) *THN Bayern. Evaluation eines Schulungsprogramms für medizinische Laien zum Einsatz von nasalem Take-Home-Naloxon in Notfallsituationen bei Menschen mit Opioidabhängigkeit in Bayern (BayTHN)*. München: Bayerisches Staatsministerium für Gesundheit und Pflege.

Wodarz-von Essen H, Wolstein J, Pogarell O, et al. (2023) Drogennotfallschulung Opioidabhängiger in Haft und Versorgung mit Take-Home Naloxon bei Haftentlassung: Machbarkeitsstudie aus dem bayerischen Modellprojekt. *Das Gesundheitswesen* 85(06): a-1860-1048.

Zimmermann M, Hilgarth H, Ittner KP, et al. (2020) Die notfallpharmakologische Bedeutung von nasal appliziertem Naloxon. *NOTARZT* 36(06). Georg Thieme Verlag KG: 317–319.

Zinberg N (1959) *Drug, Set, And Setting: The Basis for Controlled Intoxicant Use*. 1st edition. London: Yale University Press.

https://doi.org/10.5771/9783748943235-117 https://www.inlibra.com/de/page/agb - Open Access - (cc) BY